Binding domains for blockers and substrates on the cloned human dopamine transporter studied by protection against N-ethylmaleimide-induced reduction of 2β-carbomethoxy-3β-(4-fluorophenyl)[3H]tropane ([3H]WIN 35,428) binding

Biochemical Pharmacology

Volumn 52, Issue 9, 1996, Pages 1435-1446

  Reith, Maarten E A ^a   Xu, Cen ^b   Coffey, Lori L ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

^b ILLINOIS STATE UNIVERSITY   (United States)

Author keywords

cocaine binding; dopamine binding; human dopamine transporter; N ethylmaleimide; protein modification; WIN 35,428 binding

Indexed keywords

1 [1 (2 BENZO[B]THIENYL)CYCLOHEXYL]PIPERIDINE; 3BETA (4 FLUOROPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; BENZATROPINE; COCAINE; DEXAMPHETAMINE; DOPAMINE; DOPAMINE TRANSPORTER; N ETHYLMALEIMIDE; NORADRENALIN; RADIOLIGAND; VANOXERINE;

ALKYLATION; AMINE TRANSPORT; ANIMAL CELL; ARTICLE; BINDING COMPETITION; BINDING SITE; CONCENTRATION RESPONSE; CONTROLLED STUDY; GLIOMA CELL; HUMAN; MEMBRANE BINDING; MODEL; MOLECULAR CLONING; NONHUMAN; PRIORITY JOURNAL; PROTECTION; PROTEIN CONFORMATION; PROTEIN DOMAIN; RAT; RECEPTOR BINDING;

ANIMALS; BINDING SITES; CARRIER PROTEINS; CELL MEMBRANE; CLONING, MOLECULAR; COCAINE; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOPAMINE UPTAKE INHIBITORS; ETHYLMALEIMIDE; HUMANS; KINETICS; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; NERVE TISSUE PROTEINS; RATS; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0030575913     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(96)00508-4     Document Type: Article

References (67)

1. 1. Amara SG and Kuhar MJ, Neurotransmitter transporters: Recent progress. Annu Rev Neurosci 16: 73-93, 1993.
2. 2. Giros B and Caron MG, Molecular characterization of the dopamine transporter. Trends Pharmacol Sci 14: 43-49, 1993.
3. 3. Uhl GR and Johnson PS, Neurotransmitter transporters: Three important gene families for neuronal function. J Exp Biol 196: 229-236, 1994.
4. 4. Ross SB, Pharmacological and toxicological exploitation of amine transporters. Trends Pharmacol Sci 8: 227-231, 1987.
5. 5. Zimanyi I, Lajtha A, and Reith MEA, Comparison of characteristics of dopamine uptake and mazindol binding in mouse striatum. Naunyn Schmiedelbergs Arch Pharmacol 340: 626-632, 1989.
6. 6. Reith MEA, Cocaine receptors on monoamine transporters and sodium channels. In: Mechanisms of Cocaine Abuse and Toxicity, NIDA Research Monograph (Eds. Clouet D, Asghar K and Brown R), Vol. 88, pp. 23-43. U.S. Government Printing Office, Washington, DC, 1988.
7. 7. Rothman RB, Grieg N, Kim A, De Costa BR, Rice KC, Carroll FI and Pert A, Cocaine and GBR12909 produce equivalent motoric responses at different occupancy of the dopamine transporter. Pharmacol Biochem Behav 43: 1135-1142, 1992.
8. 8. Simoni D, Stoelwinder J, Kozikowski AP, Johnson KM, Bergmann JS and Ball RG, Methoxylation of cocaine reduces binding affinity and produces compounds of differential binding and dopamine uptake inhibitory activity: Discovery of a weak cocaine "antagonist." J Med Chem 36: 3975-3977, 1993.
9. 9. Rothman RB, High affinity dopamine reuptake inhibitors as potential cocaine antagonists: A strategy for drug development. Life Sci 46: PL17-PL21, 1990.
10. 10. Baumann MH, Char GU, De Costa BR, Rice KC and Rothman RB, GBR12909 attenuates cocaine-induced activation of mesolimbic dopamine neurons in the rat. J Pharmacol Exp Ther 271: 1216-1222, 1994.
11. 3H]nomifensine to striatal membranes. Biochem Pharmacol 34: 1137-1144, 1985.
12. 12. Reith MEA, Meisler BE, Sershen H and Lajtha A, Structural requirements for cocaine congeners to interact with dopamine and serotonin uptake sites in mouse brain and to induce stereotyped behavior. Biochem Pharmacol 35: 1123-1129, 1986.
13. 3H]GBR-12935 binding in brain: A radioligand for selective labelling of the dopamine transport complex. J Neurochem 46: 1272-1276, 1986.
14. 14. Schomig E, Korber M and Bonisch H, Kinetic evidence for a common binding site for substrates and inhibitors of the neuronal noradrenaline carrier. Naunyn Schmiedelbergs Arch Pharmacol 337: 626-632, 1988.
15. 15. Rudnick G and Clark J, From synapse to vesicle: The reuptake and storage of biogenic amine neurotransmitters. Biochim Biophys Acta 1144: 249-263, 1993.
16. 16. Reith MEA, Zimanyi I and O'Reilly CA, Role of ions and membrane potential in uptake of serotonin into plasma membrane vesicles from mouse brain. Biochem Pharmacol 38: 2091-2097, 1989.
17. 17. Reith MEA and Selmeci G, Radiolabeling of dopamine uptake sites in mouse striatum: Comparison of binding sites for cocaine, mazindol, and GBR 12935. Naunyn Schmiedebergs Arch Pharmacol 345: 309-318, 1992.
18. 18. Richelson E and Pfenning M, Blockade by antidepressants and related compounds of biogenic amine uptake into rat brain synaptosomes: Most antidepressants selectively block norepinephrine uptake. Eur J Pharmacol 104: 277-286, 1984.
19. 19. Shank RP, Gardocki JF, Schneider CR, Vaught JL, Setler PE, Maryanoff BE and McComsey DF, Preclinical evaluation of McN-5707 as a potential antidepressant. J Pharmacol Exp Ther 242: 74-84, 1987.
20. 20. Krueger BK, Kinetics and block of dopamine uptake into synaptosomes from rat caudate nucleus. J Neurochem 55: 260-267, 1990.
21. 21. May LJ, Kuhr WG and Wightman RM, Differentiation of dopamine overflow and uptake processes in the extracellular fluid of the rat caudate nucleus with fast-scan in vivo voltammetry. J Neurochem 51: 1060-1069, 1988.
22. 22. Jones SR, Garris PA, Kilts CD and Wightman RM, Comparison of dopamine uptake in the basolateral amygdaloid nucleus, caudate-putamen, and nucleus accumbens of the rat. J Neurochem 64: 2581-2589, 1995.
23. 23. McElvain JS and Schenk JO, A multisubstrate mechanism of striatal dopamine uptake and its inhibition by cocaine. Biochem Pharmacol 43: 2189-2199, 1992.
24. 24. Wheeler DD, Edwards AM, Chapman BM and Ondo JG, Effects of cocaine on sodium dependent dopamine uptake in rat striatal synaptosomes. Neurochem Res 19: 49-56, 1994.
25. 25. Kitayama S, Shimada S, Xu H, Markham L, Donovan DM and Uhl GR, Dopamine transporter site-directed mutations differentially alter substrate transport and cocaine binding. Proc Nad Acad Sci USA 89: 7782-7785, 1992.
26. 26. Davis S, Wang JB and Uhl GR, The phenyl ring of tyrosine 250 of the dopamine transporter is required for high-affinity binding of cocaine analogs. Soc Neurosci Abstr 20: 922, 1994.
27. 27. Kitayama S, Wang JB and Uhl GR, Dopamine transporter mutants selectively enhance MPP transport. Synapse 15: 58-62, 1993.
28. 28. Giros B, Wang Y-M, Suter S, McLeskey SB, Pifl C and Caron MG, Delineation of discrete domains for substrate, cocaine, and tricyclic antidepressant interactions using chimeric dopamine-norepinephrine transporters. J Biol Chem 269: 15985-15988, 1994.
29. 29. Reith MEA, de Costa B, Rice KC and Jacobson AE, Evidence for mutually exclusive binding of cocaine, BTCP, GBR 12935, and dopamine to the dopamine transporter. Eur J Pharmacol 227: 417-425, 1992.
30. 125I]iodophenyl)tropane binding. Mol Pharmacol 43: 264-270, 1993.
31. 31. Kennedy LT and Hanbauer I, Sodium-sensitive cocaine binding to rat striatal membrane: Possible relationship to dopamine uptake sites. J Neurochem 41: 172-178, 1983.
32. 3H]tropane to the dopamine uptake carrier. J Neurochem 61: 167-177, 1993.
33. 3H]mazindol binding sites from alkylation by N-ethylmaleimide. Eur J Pharmacol 227: 411-415, 1992.
34. 34. Heron C, Costentin J and Bonnet JJ, Evidence that pure uptake inhibitors including cocaine interact slowly with the dopamine neuronal carrier. Eur J Pharmacol 264: 391-398, 1994.
35. 3H]GBR 12935 binding in vitro to rat striatal membranes: Labeling of the dopamine uptake complex. J Neurochem 48: 1887-1896, 1987.
36. 3H]DA-uptake-inhibition to transporter-binding-inhibition ratios for the in vitro evaluation of putative cocaine antagonists. Life Sci 53: PL267-PL272, 1993.
37. 3H]WIN 35,428 binding to the dopamine uptake carrier. I. Effect of tonicity and buffer composition. J Neurosci Methods 51: 23-30, 1994.
38. 3H]WIN 35,428 binding to the dopamine uptake carrier. IL Effect of membrane fractionation procedure and freezing. J Neurosci Methods 51: 31-40, 1994.
39. 39. Xu C, Coffey LL and Reith MEA, Translocation of dopamine and binding of 2β-carbomethoxy-3 β-(4-fluorophenyl) tropane (WIN 35,428) measured under identical conditions in rat striatal synaptosomal preparations. Inhibition by various blockers. Biochem Pharmacol 49: 339-350, 1995.
40. 3H]GBR 12935 to rat and bovine striata. Membr Biochem 10: 129-144, 1993.
41. 3H]mazindol. J Pharmacol Exp Ther 253: 1206-1214, 1990.
42. 3H]cocaine in striatum and its relationship to the dopamine transporter. Membr Biochem 7: 87-106, 1988.
43. 43. Eshleman AJ, Henningsen RA, Neve KA and Janowsky A, Release of dopamine via the human transporter. Mol Pharmacol 45: 312-316, 1994.
44. 44. Eshleman AJ, Neve RL, Janowsky A and Neve KA, Characterization of a recombinant human dopamine transporter in multiple cell lines. J Pharmacol Exp Ther 274: 276-283, 1994.
45. 45. De Lean A, Munson PJ and Rodbard D, Simultaneous analysis of families of sigmoidal curves: Application to bioassay, radioligand assay and physiological dose-response curves. Am J Physiol 235: E97-E102, 1978.
46. 46. Munson PJ and Rodbard D, LIGAND: A versatile computerized approach for characterization of ligand-binding systems. Anal Biochem 107: 220-239, 1980.
47. 50) of an enzymatic reaction. Biochem Pharmacol 22: 3099-3108, 1973.
48. 48. Benda P, Lightbody J, Sato G, Levine L and Sweet W, Differentiated rat glial cell strain in tissue culture. Science 161: 370-371, 1968.
49. 49. Boja JW, Markham L, Patel A, Uhl G and Kuhar MJ, Expression of a single dopamine transporter cDNA can confer two cocaine binding sites. Neuroreport 3: 247-248, 1992.
50. 50. Carroll FI, Lewin AH, Boja JW and Kuhar MJ, Cocaine receptor: Biochemical characterization and structure-activity relationships of cocaine analogues at the dopamine transporter. J Med Chem 35: 969-981, 1992.
51. 3H]GBR 12,935 binding. Mol Pharmacol 45: 125-135, 1994.
52. 52. Gu H, Wall SC and Rudnick G, Stable expression of biogenic amine transporters reveals differences in inhibitor sensitivity, kinetics, and ion dependence. J Biol Chem 269: 7124-7130, 1994.
53. 125I]RTL-55. J Pharmacol Exp Ther 270: 296-309, 1994.
54. 125I]RTI-55 binding to recombinant human serotonin and dopamine transporters expressed in mammalian cell lines. Soc Neurosci Abstr 20: 293, 1994.
55. 3H]threo-(±)-methylphenidate to the stimulant recognition site, Neuropharmacolugy 29: 901-908, 1990.
56. 56. Saadouni S, Refahi-Lyamani F, Costentin J and Bonnet JJ, Cocaine and GBR 12783 recognize nonidentical, overlapping binding domains on the dopamine neuronal carrier. Eur J Pharmacol 268: 187-197, 1994.
57. 57. Rothman RB, Mele A, Reid AA, Akunne HC, Greig N, Thurkauf A, De Costa BR, Rice KC and Pert A, GBR12909 antagonizes the ability of cocaine to elevate extracellular levels of dopamine. Pharmacol Biochem Behav 40: 387-397, 1991.
58. 3H]cocaine binding sites. Naunyn Schmiedebergs Arch Pharmacol 351:136-145, 1995.
59. 59. Tomlinson G and Hnatowich MR, Apparent competitive inhibition of radioligand binding to receptors: Experimental and theoretical considerations in the analysis of equilibrium binding data. J Recept Res 8: 809-830, 1988.
60. 60. Ehlert FJ, Estimation of the affinities of allosteric ligands using radioligand binding and pharmacological null methods. Mol Pharmacol 33: 187-194, 1987.
61. 61. Brocklehurst L. The equilibrium assumption is valid for the kinetic treatment of most time-dependent protein modification reactions. Biochem J 181: 775-778, 1979.
62. 62. Meiergerd SM and Schenk JO, Striatal transporter for dopamine: Catechol structure-activity studies and susceptibility to chemical modification. J Neurochem 62: 998-1008, 1994.
63. 3H]cocaine in mouse striatum and cerebral cortex have different dissociation kinetics. J Neurochem 46: 309-312, 1986.
64. 3H]BTCP): A new phencyclidine analog selective for the dopamine uptake complex. Eur J Pharmacol 148: 427-436, 1988.
65. 65. Meiergerd SM and Schenk JO, Kinetic evaluation of the commonality between the site(s) of action of cocaine and some other structurally similar and dissimilar inhibitors of the striatal transporter for dopamine. J Neurochem 63: 1683-1692, 1994.
66. 66. Wang JB, Moriwaki A and UhI GR, Dopamine transporter cysteine mutants: Second extracellular loop cysteines are required for transporter expression, J Neurochem 64: 1416-1419, 1995.
67. 67. Meltzer PC, Liang AY and Madras BK, The discovery of an unusually selective and novel cocaine analog: Difluoropine, synthesis and inhibition of binding at cocaine recognition sites. J Med Chem 37: 2001-2010, 1994.